Cancer Care Observational Study
The role of repurposed drugs and metabolic interventions in the treatment of cancer
About The Cancer Care Observational Study
The Leading Edge Clinic is participating in an Observational Cancer Care Study funded by Rebuild Medicine. The study is designed to assess the effectiveness of Ivermectin and/or other repurposed drugs for cancer treatment, primarily the remission of malignant tumors. Patients who are already undergoing cancer treatment may be eligible to receive these repurposed drugs along with their current treatment plan.
Below you will find more information about the study scope, data collection, care program/treatment, frequently asked questions, additional resources, and how to be part of the study
Study Scope
This research project will follow patients’ care for a five year period, which will provide researchers insight into the safety and effectiveness of adding these repurposed drugs to treatment regimens, as well as other drug and metabolic therapies provided by our practice in patient treatment. While practitioners may use a variety of repurposed drugs and functional medicine approaches, including dietary interventions, Ivermectin will be the core additional medication used in most research subjects. Depending on your circumstances and wishes, you may concurrently receive “conventional” cancer treatments while participating in this study.
About Data Collection
The Rebuild Medicine data collection team will be contacting patients specific milestones: six-months, twelve months, eighteen months, twenty-four months, three years, four years, and five years following patient entry into study. If at any time, a patient is lost to followup, the team will contact the patient by telephone to obtain updated information about the study.
About Adjunctive Cancer Care
If you are thinking about enrolling in the study, and/or want to receive care using repurposed drugs and metabolic interventions, please visit our Adjunctive Cancer Care website page. Here you will find pertinent info around the treatment program structure, associated costs, and other info.
Frequently Asked Questions
Can I still do traditional oncological treatments if I am part of your study?
Of course you can. The word “adjunctive” implies that this program is added to something else (ie: traditional treatment). Studies show that repurposed drugs actually help improve the outcomes of chemo and radiation treatments. For example, some Ivermectin studies, like this one, show it can reverse multi-drug resistance of cancer to chemo treatments. We will, of course, continue to monitor for possible drug and supplement interactions as your oncologist makes changes to your traditional treatments. As an Observational Study, you will not be dropped for refusing therapies we recommend, or moving forward with therapies that aren’t part of our program.
For more information about the synergistic effects of our program, with traditional onology treatments, please consult Dr. Marik’s book
Do I have to continue traditional treatments with your program?
No, you do not have to participate in traditional cancer treatments, if you do not want to. We have patients who make an informed decision to only pursue the use of repurposed drugs and nutraceutical supplements, and metabolic interventions. We also have patients who have exhausted all their options with traditional treatments. We highly recommend doing your due diligence when making this decision. As mentioned in the above FAQ answer, many of our treatments enhance the outcomes of traditional oncological standard of care, and we will not bar you from the study or care should you choose to forego traditional treatment.
Do I have to follow your treatments exactly as prescribed?
This is an Observational Study. As such, patients will not be refused treatment if they decide a certain therapy isn’t right for them, or isn’t well-tolerated. Unlike RCTs funded by large pharmaceutical companies, we aren’t going to cherry-pick participants and data in order to prove a hypothesis.
How long is the study?
The study follows patients for 5 years.
Are any other practices participating?
There are no other practices participating in the observational study
What does treatment look like?
Visit our Adjunctive Cancer Care website page to learn more about the care program
Additional Adjunctive Cancer Care Resources
See Our Providers
Learn more about our providers delivering Adjunctive Cancer Care Treatment
The Role of Repurposed Drugs & Metabolic Interventions in Cancer
The Role Of Repurposed Drugs And Metabolic Interventions In Treating Cancer is Dr. Paul Marik’s amalgamation of research into the existing scientific evidence behind: 1) the metabolic theory of cancer; 2) the role and safety of over 250+ repurposed drugs and over 2,000+ repurposed supplements to treat cancer summarized into recommendations for and against; and 3) the role of metabolic interventions such as dietary changes, exercise, sleep, and sunshine. Learn more about the science behind the therapies being observed in the study
The Scientific Basis for the Somatic Mutation Theory of Cancer is Invalid
In this substack article. Dr. Pierre Kory addresses the logical fallacies behind the Somatic Theory of Cancer, which has been the driving theory behind decades of treatment “innovation”, resulting in many hundreds of targeted therapies. Through all the many billions of dollars in research funding, and hundreds of new treatments, the 5 year survival rates of cancer have remained the same. As Dr. Kory dispels the existing scientific literature, readers will begin to understand why further studies and research are needed on treatments that address metabolic approaches, instead of the universally accepted somatic-based approaches.
The Evolution and Validation of the Metabolic Theory of Cancer
In this substack article, Dr. Kory discusses the nearly lost history of research behind The Metabolic Theory of Cancer, which is the driving theory behind how we approach and care for patients with our adjunctive cancer care program. Research began in the 1920s by Dr. Otto Warburg. His findings were eventually validated through others’ research both intentionally and unintentionally; proving that metabolic dysfunction and oxidative stress originating in the energy producing centers of the cell causes the downstream effects that we refer to as cancer.